Traws Pharma, Inc. has announced the approval to proceed with Phase 2 clinical studies for ratutrelvir, a ritonavir-free treatment for newly diagnosed COVID-19 patients. The trials will assess the safety and efficacy of ratutrelvir compared to the current standard, PAXLOVID®, and in PAXLOVID®-ineligible subjects. The studies aim to address issues such as disease rebound and Long COVID incidence, particularly among vulnerable populations with limited treatment options. Traws Pharma expects to present the top-line data from both trials by the end of 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-079454), on August 18, 2025, and is solely responsible for the information contained therein.